Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database

BACKGROUND: The introduction of immune checkpoint inhibitors (ICIs) in clinical practice has brought significant benefits for patients. Seven ICIs are available in Europe: nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab, and ipilimumab. Despite their proven clinical efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruggiero, Rosanna, Fraenza, Federica, Scavone, Cristina, di Mauro, Gabriella, Piscitelli, Raffaele, Mascolo, Annamaria, Ferrajolo, Carmen, Rafaniello, Concetta, Sportiello, Liberata, Rossi, Francesco, Capuano, Annalisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295943/
https://www.ncbi.nlm.nih.gov/pubmed/32581796
http://dx.doi.org/10.3389/fphar.2020.00830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295943/
https://www.ncbi.nlm.nih.gov/pubmed/32581796
http://dx.doi.org/10.3389/fphar.2020.00830

Ejemplares similares